Pharmacological profile of anti-human TNF.ALPHA. monoclonal antibody, infliximab (Remicade).

  • SUGITA Takahisa
    Biology and Pharmacology Department, Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd.

Bibliographic Information

Other Title
  • インフリキシマブ(レミケード)―抗ヒトTNFαモノクローナル抗体製剤―の免疫・炎症性疾患に対する薬効薬理
  • 新薬紹介総説 インフリキシマブ(レミケード)--抗ヒトTNFαモノクローナル抗体製剤--の免疫・炎症性疾患に対する薬効薬理
  • シンヤク ショウカイ ソウセツ インフリキシマブ レミケード コウヒト TNF アルファ モノクローナル コウタイ セイザイ ノ メンエキ エンショウセイ シッカン ニ タイスル ヤッコウ ヤクリ

Search this article

Description

TNFα (tumor necrosis factor-alpha) plays an important role in the pathogenesis of inflammatory diseases including Crohn's disease and rheumatoid arthritis. Infliximab (Remicade®) is a chimeric monoclonal antibody that recognizes human TNFα. Clinical trials have been persuasive that infliximab is effective in both Crohn's disease and rheumatoid arthritis. Infliximab is an important treatment option in patients with active Crohn's disease who have not responded to conventional therapy and in patients with Crohn's disease who have fistulae. Moreover, infliximab plus methotrexate is effective in patients with active rheumatoid arthritis who have not responded adequately to traditional disease-modifying anti-rheumatic drugs, in terms of reducing symptoms and signs, inhibiting the progression of structural damage and improving physical function.<br>

Journal

References(38)*help

See more

Details 詳細情報について

Report a problem

Back to top